Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
MORE►
biotechnology
Research Bridge Partners' CEO Lydia McClure, Ph.D. [Sources: Research Bridge Partners; MadamLead/istock]
Texas-Based Research Bridge Partners Taps New Board Leadership to Drive ‘High-Quality Investment Opportunities’ in Biomedical Innovation
by Quincy Preston | Aug 9, 2024
With a new CEO and three seasoned industry veterans joining its board, Research Bridge Partners is focused on moving university innovations from the lab to the marketplace.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
Last year, the Texas-based nonprofit, in collaboration with Lyda Hill Philanthropies, invested $4 million into North Texas’ UT Southwestern Medical Center, bolstering efforts to transform groundbreaking research into viable companies.
by Nicole Ward, DRC Data Journalist |
Aug 1, 2024
OncoNano's innovative approach to cancer treatment leverages nanotechnology to bring tumors into the light.
MORE►
by Quincy Preston |
Sep 18, 2023
The deal with Fresenius Kabi aims to bring innovative cell and gene treatments closer to patients by advancing Lupagen’s proprietary cell and gene therapy delivery system, the companies said. Their "to the bedside" approach could help open cutting-edge treatments to local hospitals and patients worldwide.
MORE►
by Quincy Preston |
Sep 1, 2023
Tarleton State University received the go-ahead for a new biotechnology institute as part of Texas A&M-Fort Worth’s burgeoning downtown research campus.
Approved in mid-August by the Texas A&M University System Board of Regents, the biotech institute is situated in one of the nation’s fastest-growing life sciences hubs....
MORE►
BioNTX's Dr. Aaron BenComo (left) and Swiss American CDMO CEO Komel Grover [Courtesy photos]
Swiss American CDMO and BioNTX To Launch the Biotechnology and Healthcare Industry Alliance of North Texas
by Lance Murray | Jun 14, 2023
The alliance's first event will be held June 22 in a bid to champion a next-generation, industry-led workforce partnership for North Texas. The alliance seeks to bring together industry trade and manufacturing ecosystems, the organizations said—and it will be working with Dallas College and other partner institutions to help make it happen.
MORE►
by Lance Murray |
Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE►
by Lance Murray |
Dec 8, 2022
Southlake-based Renibus Therapeutics—a clinical-stage biotech company developing innovative products for cardiorenal diseases—has received $33 million in bridge financing to help it advance three drugs in its pipeline. The drugs are currently in various phases of trials.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
MORE►
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Photo: Caris Life Sciences]
Caris Life Sciences Raises $310M to Continue Rapidly Growing in the Precision Medicine Market
by Alex Edwards | Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
by Quincy Preston |
Oct 8, 2020
This year's Nobel Prize in Chemistry, awarded to two female scientists for the development of CRISPR as a gene-editing tool, is a revolution, according to a pair of UTSW scientists.
UTSW's Eric Olson and Rhonda Bassel-Duby use the technology in their work to treat Duchenne muscular dystrophy. Olson also is the co-founder of biotech Exonics Therapeutics, which exited last year in a deal roughly valued at $1B.
MORE►
by Alex Edwards |
Sep 22, 2020
CEO Brandom Gengelbach says he’s doing business differently in the fast-growing city “where the West begins.”
MORE►
![At the Fourth Annual iC3 Life Science Summit at UT Arlington on Oct. 10, 2017 recipient Lyda Hill will present the award. To register for the summit, visit www.bionorthtx.org. [Illustration: bestbrk/istockphoto]](https://s24806.pcdn.co/wp-content/uploads/2018/09/Bionorthconcept_970_bestbrk_istockphotovector-molecule-background-genetic-and-chemical-compounds-abstract-vector-id908258902-360x203.jpg)
by Quincy Preston |
Sep 22, 2020
Networking—always a highlight of the biotech event— is still a cornerstone thanks to a new virtual conference platform, its organizers said.
MORE►
Lucas Rodriguez, CerSci [Photo: Skyler Fike]
Dallas-based Biotech CerSci Acquired by ACADIA Pharmaceutical in $52.5M Deal
by Quincy Preston | Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE►
by Quincy Preston |
Aug 20, 2020
OncoNano Medicine, a spinout of University of Texas Southwestern, uses pH as a biomarker to detect metastatic cancer. Its technology, which visualizes a tumor, could be a gamechanger.
MORE►
by Alex Edwards |
Jul 13, 2020
CAGE Bio—currently a resident at Johnson & Johnson Innovation—uses a proprietary platform to develop therapeutic products for dermatology, inflammation, and immunology.
MORE►
by Lauren Hawkins |
May 4, 2020
Last month, Allied BioScience received capital from Lydia Partners to scale its operations and meet a surging demand.
MORE►
